IPP Bureau
Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug
By IPP Bureau - January 08, 2026
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study
By IPP Bureau - January 08, 2026
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Briefs: Medicamen Biotech and Gland Pharma
By IPP Bureau - January 08, 2026
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Wockhardt files marketing authorisation application for WCK 5222 with EMA
By IPP Bureau - January 08, 2026
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India
By IPP Bureau - January 07, 2026
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'
By IPP Bureau - January 07, 2026
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
ProBioGen, Zag Bio seal manufacturing deal to fast-track type 1 diabetes therapy into clinic
By IPP Bureau - January 07, 2026
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Subcutaneous Saphnelo cuts lupus disease activity in phase III trial
By IPP Bureau - January 07, 2026
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
FDA grants priority review to Tzield for youngest Type 1 diabetes patients
By IPP Bureau - January 07, 2026
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
GSK’s Nucala approved in China for COPD with high eosinophils
By IPP Bureau - January 07, 2026
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma
By IPP Bureau - January 07, 2026
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
.jpg "MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial"){kind=logo}
MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial
By IPP Bureau - January 07, 2026
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Medera doses final patient in high-dose HFpEF gene therapy trial
By IPP Bureau - January 07, 2026
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics secures ISO 20400 certification
By IPP Bureau - January 07, 2026
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Kelun-Biotech secures IND nod for innovative cancer therapy SKB105 in China
By IPP Bureau - January 07, 2026
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
